08 May, EOD - Indian

SENSEX 80334.81 (-0.51)

Nifty 50 24273.8 (-0.58)

Nifty Bank 54365.65 (-0.45)

Nifty IT 36002.45 (0.23)

Nifty Midcap 100 53229.3 (-1.95)

Nifty Next 50 62760.25 (-2.14)

Nifty Pharma 21115.05 (-1.62)

Nifty Smallcap 100 16183.75 (-1.43)

08 May, EOD - Global

NIKKEI 225 36928.63 (0.41)

HANG SENG 22775.92 (0.37)

S&P 5696.75 (0.58)

Login/Signup
Careers
LOGIN HERE
Cancel

companylogoUnichem Laboratories Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 506690 | NSE Symbol : UNICHEMLAB | ISIN : INE351A01035 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
28-Mar-2025 28-Mar-2025 Subsidiary Company Outcome of Board Meeting
01-Mar-2025 01-Mar-2025 Others Outcome of Board Meeting - Sale of property
14-Jan-2025 06-Feb-2025 Quarterly Results UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31 2024. Unaudited Financial Results (Consolidated & Standalone) for the quarter and nine-months ended 31st December 2024 Included Mr. Uttkarsh Patil, Chief Manufacturing officer - Formulations, as a senior Management Personnel under SEBI LODR Regulations with effect from 6th February 2025 (As Per BSE Announcement dated on 06.02.2025)
25-Oct-2024 13-Nov-2024 Quarterly Results UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended September 30 2024. Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2024 (As Per BSE Announcement Dated on: 13/11/2024)
23-Sep-2024 30-Sep-2024 Others UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/09/2024 inter alia to consider and approve integration and consolidation of the generics formulations business in the US market. Purchase of Product approvals and all goodwill associated with Nine (9) ANDAs owned by Bayshore Pharmaceuticals LLC, USA for USD 2,650,000 by the Company and Purchase of USA generics formulations business as a going concern through slump sale ./ transfer of business by Unichem Pharmaceuticals (USA) Inc through assets purchase agreements for USD 10,000,000. (As per BSE Announcement dated on 30/09/2024) Board approved entering into following agreements with Bayshore Pharmaceuticals LLC, USA ('Bayshore USA') (wholly owned step-down subsidiary of Ipca Laboratories Limited, Company's holding company) for: a. Purchase all of rights, title and interest in the Product approvals and all goodwill associated with Nine (9) ANDAs owned by Bayshore USA for US dollars two million six hundred fifty thousand ($ 2,650,000) through asset purchase agreement subject to required consents and approvals, if any; and b. Unichem Pharmaceuticals (USA) Inc ('Unichem USA'), a wholly owned subsidiary of the Company, to purchase USA generics formulations marketing/distribution business of Bayshore USA (Step-down subsidiary of parent company Ipca Laboratories Ltd) as a going concern through slump sale/transfer of entire business (debt free) and all goodwill associated with the business through asset purchase agreement for US dollars ten million ($10,000,000) (As Per BSE Bulletin Dated on 04.10.2024)
26-Jul-2024 08-Aug-2024 Quarterly Results UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve Unaudited financial results (standalone & consolidated) for the quarter ended 30th June 2024. PFA herewith Outcome of Board Meeting (As Per BSE Announcement Dated on 08.08.2024)
09-May-2024 22-May-2024 Accounts UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Financial results for quarter and year ended March 31 2024 Outcome of Board Meeting PFA herewith financial results for the quarter and year ended 31st March 2024 (As Per BSE Announcement dated on 22.05.2024)
15-Jan-2024 05-Feb-2024 Quarterly Results UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2024 inter alia to consider and approve Unaudited financial results for quarter and nine months ended December 31. 2023 UNICHEM LABORATORIES LIMITED has informed BSE about Board Meeting to be held on 05 Feb 2024 to consider financial statements for the period ended December 2023. Financial results. Outcome of Board Meeting for quarter and nine months ended 31st December 2023. Results for quarter and nine months ended December 31, 2023. (As Per BSE Announcement Dated on 05/02/2024)
18-Oct-2023 01-Nov-2023 Quarterly Results UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 inter alia to consider and approve Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday November 1 2023 to inter-alia consider and approve the Unaudited Financial Results (Consolidated and Standalone) for the second quarter and six months ended September 30 2023. We would like to inform you that Board of Directors at its Meeting held today, i.e. Wednesday, November 1, 2023, approved the Unaudited Financial Results (Standalone & Consolidated) for the Second and Six months ended September 30, 2023 of the financial year 2023-24. Enclosed herewith please find the Unaudited Financial Results (Standalone & Consolidated) for the second quarter and six months ended September 30, 2023 of the financial year 2023-24, and the Auditors Reports thereon. (As Per BSE Announcement Dated on 01/11/2023)
09-Aug-2023 09-Aug-2023 Change in Directors Change in composition of the Board of Directors
05-Jul-2023 14-Jul-2023 Quarterly Results UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/07/2023 inter alia to consider and approve Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30 2023. Unaudited Financial Results (Standalone & Consolidated ) for the quarter 30.6.2023 approved by the Board on 14.7.2023 (As Per BSE Announcement Dated on 14.07.2023)
26-Jun-2023 26-Jun-2023 Change in Directors Re-appointment of Chairman & Managing Director Re-appointment of Chairman & Managing Director
15-May-2023 23-May-2023 Accounts UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve Intimation of Board meeting date for approving financial results for quarter and year ended March 31 2023 Approval of financial results for quarter and year ended 31.3.2023 (As Per BSE Announcement Dated on 23/05/2023) Financial Results for the quarter and year ended March 31, 2023, published in the newspapers on May 24, 2023. (As Per BSE Announcement dated on 24.05.2023)
24-Apr-2023 24-Apr-2023 Acquisitions Outcome of the board meeting held on 24.4.2023
20-Mar-2023 20-Mar-2023 Change in Directors Board of Directors Update
1 2 

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.
+91-22-25229720
+91-9769005430
>info@capitalmarket.com

For any Capital Market Website related queries mail to :
webdesk@capitalmarket.com

For Capital Market Magazine subscription queries :
+91-8657545825  

subscription@capitalmarket.com

For Capital Market Online Product related queries :
+91-8657545825  

financeshop@capitalmarket.com

To advertise on Capital Market Websites mail to :
advt@capitalmarket.com

To email Press Releases :
pressrelease@capitalmarket.com

Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages giving any kind of stock recommendations.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +